Helen M. Thackray - Net Worth and Insider Trading
Helen M. Thackray Net Worth
The estimated net worth of Helen M. Thackray is at least $2 Million dollars as of 2024-12-26. Helen M. Thackray is the Chief R&D Officer of BioCryst Pharmaceuticals Inc and owns about 272,139 shares of BioCryst Pharmaceuticals Inc (BCRX) stock worth over $2 Million. Helen M. Thackray is also the SVP Clinical Development, CMO of GlycoMimetics Inc and owns about 148,615 shares of GlycoMimetics Inc (GLYC) stock worth over $37,956. Details can be seen in Helen M. Thackray's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Helen M. Thackray has not made any transactions after 2024-05-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Helen M. Thackray
Helen M. Thackray Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Helen M. Thackray owns 3 companies in total, including BioCryst Pharmaceuticals Inc (BCRX) , GlycoMimetics Inc (GLYC) , and Immunogen Inc (IMGN) .
Click here to see the complete history of Helen M. Thackray’s form 4 insider trades.
Insider Ownership Summary of Helen M. Thackray
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals Inc | 2024-05-14 | director |
| GLYC | GlycoMimetics Inc | 2017-12-08 | VP Clinical Development & CMO |
| IMGN | Immunogen Inc | 2021-09-22 | director |
Helen M. Thackray Latest Holdings Summary
Helen M. Thackray currently owns a total of 2 stocks. Among these stocks, Helen M. Thackray owns 272,139 shares of BioCryst Pharmaceuticals Inc (BCRX) as of May 14, 2024, with a value of $2 Million and a weighting of 98.23%. Helen M. Thackray also owns 148,615 shares of GlycoMimetics Inc (GLYC) as of December 8, 2017, with a value of $37,956 and a weighting of 1.77%.
Latest Holdings of Helen M. Thackray
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| BCRX | BioCryst Pharmaceuticals Inc | 2024-05-14 | 272,139 | 7.72 | 2,100,913 |
| GLYC | GlycoMimetics Inc | 2017-12-08 | 148,615 | 0.26 | 37,956 |
Holding Weightings of Helen M. Thackray
Helen M. Thackray Form 4 Trading Tracker
According to the SEC Form 4 filings, Helen M. Thackray has made a total of 3 transactions in BioCryst Pharmaceuticals Inc (BCRX) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in BioCryst Pharmaceuticals Inc is the acquisition of 30,000 shares on May 14, 2024, which cost Helen M. Thackray around $175,800.
According to the SEC Form 4 filings, Helen M. Thackray has made a total of 0 transactions in GlycoMimetics Inc (GLYC) over the past 5 years. The most-recent trade in GlycoMimetics Inc is the sale of 2,000 shares on December 8, 2017, which brought Helen M. Thackray around $30,020.
Insider Trading History of Helen M. Thackray
- 1
Helen M. Thackray Trading Performance
GuruFocus tracks the stock performance after each of Helen M. Thackray's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Helen M. Thackray is 46.64%. GuruFocus also compares Helen M. Thackray's trading performance to market benchmark return within the same time period. The performance of stocks bought by Helen M. Thackray within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Helen M. Thackray's insider trading performs compared to the benchmark.
Performance of Helen M. Thackray
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 15.11 |  | | | | |
| Relative Return to S&P 500(%) | 11.59 | | | | | |
Helen M. Thackray Ownership Network
Helen M. Thackray Owned Company Details
What does BioCryst Pharmaceuticals Inc do?
Who are the key executives at BioCryst Pharmaceuticals Inc?
Helen M. Thackray is the director of BioCryst Pharmaceuticals Inc. Other key executives at BioCryst Pharmaceuticals Inc include Chief Financial Officer Anthony Doyle , Vice President and CCO Charles K Gayer , and VP & General Counsel & Corp Sec Alane P Barnes .
BioCryst Pharmaceuticals Inc (BCRX) Insider Trades Summary
Over the past 18 months, Helen M. Thackray made 1 insider transaction in BioCryst Pharmaceuticals Inc (BCRX) with a net purchase of 30,000. Other recent insider transactions involving BioCryst Pharmaceuticals Inc (BCRX) include a net sale of 2,000 shares made by Nancy J Hutson , a net purchase of 36,300 shares made by Anthony Doyle , and a net purchase of 30,000 shares made by Jon P Stonehouse .
In summary, during the past 3 months, insiders sold 7,000 shares of BioCryst Pharmaceuticals Inc (BCRX) in total and bought 0 shares, with a net sale of 7,000 shares. During the past 18 months, 26,987 shares of BioCryst Pharmaceuticals Inc (BCRX) were sold and 183,601 shares were bought by its insiders, resulting in a net purchase of 156,614 shares.
BioCryst Pharmaceuticals Inc (BCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
BioCryst Pharmaceuticals Inc Insider Transactions
Helen M. Thackray Mailing Address
Above is the net worth, insider trading, and ownership report for Helen M. Thackray. You might contact Helen M. Thackray via mailing address: C/o Glycomimetics, Inc., 401 Professional Drive, Suite 250, Gaithersburg Md 20879.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
